Rheumatologists can’t ignore hypereosinopilic syndrome anymore, not when it borders on our diseases and therapies. Great takeaways on subtypes and therapies from Giacomo Emmi in an elegant talk #EULAR2025 @RheumNow https://t.co/yzQVt1fLKW https://t.co/kiX6kPPQP5

#EULAR2025 in numbers 💫5125 abstracts submitted from 95 countries 💫177 scientific sessions 💫350 speakers from 45 nations 💫Balanced gender split of speakers & chairpersons 💫Fresh sessions format 💫Integration of European Workshop for Rheum Research https://t.co/7WoknFuVLL

Glucocorticoid Tapering in SLE Dr. Yuz Yusof discusses abstract POS1224 presented at the 2025 EULAR meeting in Barcelona, Spain. https://t.co/oI992YLvnB https://t.co/mPmMxcpMey

GLP 1 Receptor Agonists in axSpA Dr. David Liew reviews POS1232 presented at the 2025 EULAR meeting in Barcelona, Spain. https://t.co/88Ms7ce7XX https://t.co/tt3qZH1hJT

Rituximab - Super Responders Exist in SLE Dr. Yuz Yusof reports on abstract POS0325 presented at the 2025 EULAR meeting in Barcelona. https://t.co/LkYzMtsErn https://t.co/awRhQmbhoT

Rheumatology RoundUp: EULAR 2025 https://t.co/csWNjWyIg7 https://t.co/B6AvK1zBqX

PCR: Prevalence, Cost, & Risk (6.27.2025) Dr. Jack Cush reviews the news and journal reports from last week on RheumNow. https://t.co/zt0OxwQ2BO https://t.co/eFqHwROQOj

New IL-17 Inhibition New Molecular Constructs Dr. Philip Mease offers his perspective from the 2025 EULAR meeting in Barcelona, Spain. https://t.co/zz4NRITsRN https://t.co/FrUbmsjxxB

A Review of Intracranial GCA A comprehensive review in Rheumatology on intracranial giant cell arteritis (icGCA) stresses that GCA is both an intracranial and extracranial large vessel vasculitis, with the former having unique presentations, and outcomes. https://t.co/NkN4gfcq3n

HLA-B27 Testing in Practice A single center study shows HLA-B27 testing is often performed by both by rheumatologists and nonrheumatologists for a wide array of reasons and often along with other serologic tests. Optimal use of HLA-B27 testing has yet to be defined. https://t.co/oq7GNhzwZd

ARD's Impact Factor The 2024 Impact Factor for ARD is 20.6 – an increase from 20.3 in 2023. This retains the journal’s position as second of 58 titles in the rheumatology category and confirms its status as the top-ranking journal for the publication of original research in both https://t.co/dtMTejkhcc

JAMA Clinical Challenge - 34-yoF with Forearm Pain and Stiffness. 1 yr of progressive skin tightening over forearms, tibia, LOM of fingers & elbows. Denied DM, Raynauds. Worse after tennis, better w/ steroids. Increased ANA, eosinophils, CRP, aldolase - your Dx? https://t.co/5VrE4OpZ4N